Tracers / [18F]SiTATE
[18F]SiTATE
Also written as [18F]SiTATE; [F-18]SiTATE
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 14
What it is
- Compound class
- Radiolabelled somatostatin analogue peptide (silicon-fluoride-acceptor SiFA-TATE conjugate)
- Target / mechanism
- Somatostatin receptor subtype 2 (SSTR2) PMID 40445313
- Clinical application
- Neuroendocrine tumour and phaeochromocytoma/paraganglioma PET imaging PMID 40445313
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Scintomics GRP 2V Scintomics | custom manifold | SPE | 53 ± 10 no | 97 ± 0.9% | SiTATE precursor | 37819534 2023 EJNMMI Radiopharm Chem The process was developed on a Scintomics GRP™ 2V automated synthesis unit (ASU) — average radiochemical yields of 53 ± 10% end-of-synthesis |
| Modular-Lab (model not stated) Eckert & Ziegler | — | SPE | 32 ± 1 yes | — | SiTATE precursor | 37819534 2023 EJNMMI Radiopharm Chem At University Medical Center Groningen, an Eckert and Ziegler modular lab system is used. — The average decay-corrected radiochemical yield is 32 ± 1% (n = 3). |
| TRACERlab MX GE HealthCare | vendor cassette | SPE | — | — | — ABX | 37819534 2023 EJNMMI Radiopharm Chem ABX has developed a process for the GE TRACERlab MX as well as for the ORA Neptis® RS/DB synthesizer. |
| Neptis Plug / Neptis RS ORA | vendor cassette | SPE | — | — | — ABX | 37819534 2023 EJNMMI Radiopharm Chem as well as for the ORA Neptis® RS/DB synthesizer |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 40 ± 5 no | ≥ 95% | — | 37819534 2023 EJNMMI Radiopharm Chem RQS (Ruffani Quality Solutions) provides a novel process to be implemented on the Trasis AllinOne ASU without the need of any HPLC equipment. — an overall yield of 40 ± 5% (n = 5) end-of-synthesis |
| — | — | — | — | — | — ABX | 36793617 2023 Front Oncol |
| — | — | — | — | — | — | 42141279 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 41693498 2026 Nucl Med Commun |
| — | — | — | — | — | — | 40970962 2026 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — ABX | 40445313 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 40188826 2025 Neuroendocrinology |
| — | — | — | 53 no | 97 | — | 38769164 2024 Eur Radiol |
| — | — | — | — | — | — ABX | 33928401 2021 Eur J Nucl Med Mol Imaging |
| — | — | — | 54 ± 4% no | 96.3 ± 0.1% | — | 32828007 2020 Nucl Med Biol on the Scintomics GRP™ platform for clinical NET imaging — [18F]SiTATE was obtained in 54 ± 4% (n = 3) non-decay corrected radiochemical yield (RCY) |
Need this precursor?We can point you to suppliers for [18F]SiTATE, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]SiTATE.
Get in touchNotes
Added from reverse module search (stage 6); 5 article(s) with F-18.